The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Autologous and allogeneic hematopoietic cell transplantation (HCT) have a long history in the treatment of lymphoma. The curative potential of autologous HCT was first demonstrated in lymphoma, and this approach continues to play a central role in the management of relapsed disease. The initial experience with allogeneic HCT in lymphoma was limited by prohibitive toxicity and transplant‐related mortality...
Targeted busulfan ( T BU) and cyclophosphamide (CY) for allogeneic hematopoietic cell transplantation carries a high risk of sinusoidal obstruction syndrome (SOS) in patients undergoing transplantation for myelofibrosis. We tested the hypothesis that reversing the sequence of administration (from T BU/CY to CY/ T BU) would reduce SOS and day +100 nonrelapse mortality. We enrolled...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.